Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Escitalopram Doses up to 50mg in Treatment of MDD

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* written informed consent will be obtained from each patient~* aged 18 to 65 inc~* suffering from MDD as defined by DSM IV~* have been taking citalopram in a dose of at least 20mg for at least six weeks~* an inadequate response -- defined as failure to achieve a MADRS score of \<12~Exclusion Criteria:~* Significant other psychiatric disorder which would interfere with trial assessments. Co-morbid generalized anxiety disorder (GAD) and panic will be permitted where MDD is considered the primary diagnosis .~* history of mania or bipolar disorder~* Known contraindication for the use of citalopram or escitalopram.~* Significant bleeding disorder~* Prominent suicidal ideation (score more than 4 in the MADRS suicidal thoughts item)~* Alcohol or substance dependence in the past 6 months~* Major physical illness~* Significant liver or renal function abnormality~* Significant ECG abnormalities~* Pregnant or lactating females~* Inadequate contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Active (Type: EXPERIMENTAL): Active escitalopram

Based on this trial design, predict the completion outcome and termination type (if applicable).